CST’s PhosphoScan proteomics technology is a patented methodology that enables the discovery of drug target phospho-profiles (PhosphoSignatures) in cells and disease tissues. In the current research project, PhosphoScan will be employed to validate phosphorylation site biomarkers on target kinases for antibody development, which is being pursued under a parallel research alliance between CST and AstraZeneca.
Christopher Bunker, director of business development at CST, said: “We aim to provide AstraZeneca with valuable information based on PhosphoScan discovery and then translate that information into biomarker assays with our proprietary antibody technology.”